nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.06.2011

Current State of Our Knowledge on Brain Tumor Epidemiology

verfasst von: Quinn T. Ostrom, Jill S. Barnholtz-Sloan

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The overall incidence of brain tumors for benign and malignant tumors combined is 18.71 per 100,000 person-years; 11.52 per 100,000 person-years for benign tumors and 7.19 per 100,000 person-years for malignant tumors. Incidence, response to treatment, and survival after diagnosis vary greatly by age at diagnosis, histologic type of tumor, and degree of neurologic compromise. The only established environmental risk factor for brain tumors is ionizing radiation exposure. Exposure to radiofrequency electromagnetic fields via cell phone use has gained a lot of attention as a potential risk factor for brain tumor development. However, studies have been inconsistent and inconclusive due to systematic differences in study designs and difficulty of accurately measuring cell phone use. Recently studies of genetic risk factors for brain tumors have expanded to genome-wide association studies. In addition, genome-wide studies of somatic genetic changes in tumors show correlation with clinical outcomes.

• CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 2004–2006. Chicago: Central Brain Tumor Registry of the United States; 2010. This CBTRUS report shows the most recent population-based incidence, prevalence, and survival statistics for all brain tumors in the United States.

Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002;4:278–99.PubMed

Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl). 2005;109(1):93–108.CrossRef

Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113(7 Suppl):1953–68.PubMedCrossRef

• Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41(8):899–904. This study was the first to publish results from GWAS and glioma risk. Even though this study used different study populations and different study criteria, they found multiple statistically significant “GWAS hits” in common.PubMedCrossRef

• Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41(8):905–8. This study was the first to publish results from GWAS and glioma risk. Even though this study used different study populations and different study criteria, they found multiple statistically significant “GWAS hits” in common.PubMedCrossRef

•• The INTERPHONE Study Group: Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol. 2010;39(3):675–94. This is the most recent report on the association between cell phone use and brain tumor risk coming from the largest study performed to date, the INTERPHONE study. This study concludes that there is no association between cell phone use and brain tumor risk, except for risk of glioma associated with the top decile of cumulative cell phone use.CrossRef

Law ME, Templeton KL, Kitange G, et al. Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet. 2005;160(1):1–14.PubMedCrossRef

Thomas C, Ely G, James CD, et al. Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. Acta Neuropathol (Berl). 2001;101(6):605–15.

10.

Smith JS, Tachibana I, Lee HK, et al. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosom Cancer. 2000;29(1):16–25.PubMedCrossRef

11.

Wiencke JK, Aldape K, McMillan A, et al. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomark Prev. 2005;14(7):1774–83.CrossRef

12.

Kleihues P, Ohgaki H. Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol. 1997;7:1131–6.CrossRef

13.

Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 1999;1(1):44–51.PubMed

14.

Kleihues P, Ohgaki H. Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicol Pathol. 2000;28(1):164–70.PubMedCrossRef

15.

Berens ME, Giese A. “...those left behind.” Biology and oncology of invasive glioma cells. Neoplasia. 1999;1(3):208–19.PubMedCrossRef

16.

Berens ME, Rutka JT, Rosenblum ML. Brain tumor epidemiology, growth, and invasion. Neurosurg Clin N Am. 1990;1(1):1–18.PubMed

17.

Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892–9.PubMedCrossRef

18.

The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.CrossRef

19.

Bredel M, Scholtens DM, Harsh GR, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA. 2009;302(3):261–75.PubMedCrossRef

20.

Cowin PA, Anglesio M, Etemadmoghadam D, Bowtell DD. Profiling the cancer genome. Annu Rev Genomics Hum Genet. 2010;11:133–59.PubMedCrossRef

21.

Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol. 2010;28(16):2777–83.PubMedCrossRef

22.

• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. This study used the GB Cancer Genome Atlas (TCGA) data set to validate the previously described GB subtypes, which are each hallmarked by specific genomic aberrations and/or dysregulated gene expression.PubMedCrossRef

23.

Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157–73.PubMedCrossRef

24.

Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64(18):6503–10.PubMedCrossRef

25.

Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003;63(7):1602–7.PubMed

26.

Li A, Walling J, Ahn S, et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 2009;69(5):2091–9.PubMedCrossRef

27.

Rich JN, Hans C, Jones B, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005;65(10):4051–8.PubMedCrossRef

28.

Lee Y, Liu J, Patel S, et al. Genomic landscape of meningiomas. Brain Pathol. 2010;20(4):751–62.PubMedCrossRef

29.

Auvinen A, Hietanen M, Luukkonen R, Koskela RS. Brain tumors and salivary gland cancers among cellular telephone users. Epidemiology. 2002;13(3):356–9.PubMedCrossRef

30.

Christensen HC, Schuz J, Kosteljanetz M, et al. Cellular telephones and risk for brain tumors: a population-based, incident case-control study. Neurology. 2005;64(7):1189–95.PubMed

31.

Hardell L, Carlberg M, Hansson Mild K. Pooled analysis of two case-control studies on use of cellular and cordless telephones and the risk for malignant brain tumours diagnosed in 1997–2003. Int Arch Occup Environ Health. 2006;79(8):630–9.PubMedCrossRef

32.

Hepworth SJ, Schoemaker MJ, Muir KR, et al. Mobile phone use and risk of glioma in adults: case-control study. BMJ. 2006;332(7546):883–7.PubMedCrossRef

33.

Hours M, Bernard M, Montestrucq L, et al. Cell Phones and Risk of brain and acoustic nerve tumours: the French INTERPHONE case-control study. Rev Épidémiol Santé Publique. 2007;55(5):321–32.PubMed

34.

Inskip PD, Tarone RE, Hatch EE, et al. Cellular-telephone use and brain tumors. N Engl J Med. 2001;344(2):79–86.PubMedCrossRef

35.

Klaeboe L, Blaasaas KG, Tynes T. Use of mobile phones in Norway and risk of intracranial tumours. Eur J Cancer Prev. 2007;16(2):158–64.PubMedCrossRef

36.

Lahkola A, Auvinen A, Raitanen J, et al. Mobile phone use and risk of glioma in 5 North European countries. Int J Cancer. 2007;120(8):1769–75.PubMedCrossRef

37.

Lonn S, Ahlbom A, Hall P, Feychting M. Long-term mobile phone use and brain tumor risk. Am J Epidemiol. 2005;161(6):526–35.PubMedCrossRef

38.

Muscat JE, Malkin MG, Thompson S, et al. Handheld cellular telephone use and risk of brain cancer. JAMA. 2000;284(23):3001–7.PubMedCrossRef

39.

Schuz J, Bohler E, Berg G, et al. Cellular phones, cordless phones, and the risks of glioma and meningioma (Interphone Study Group, Germany). Am J Epidemiol. 2006;163(6):512–20.PubMedCrossRef

40.

Takebayashi T, Varsier N, Kikuchi Y, et al. Mobile phone use, exposure to radiofrequency electromagnetic field, and brain tumour: a case-control study. Br J Cancer. 2008;98(3):652–9.PubMedCrossRef

41.

Hardell L, Carlberg M, Hansson Mild K. Pooled analysis of two case-control studies on the use of cellular and cordless telephones and the risk of benign brain tumours diagnosed during 1997–2003. Int J Oncol. 2006;28(2):509–18.PubMed

42.

Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol. 39(3):675–94.

43.

Lahkola A, Salminen T, Raitanen J, et al. Meningioma and mobile phone use–a collaborative case-control study in five North European countries. Int J Epidemiol. 2008;37(6):1304–13.PubMedCrossRef

44.

Christensen HC, Schuz J, Kosteljanetz M, et al. Cellular telephone use and risk of acoustic neuroma. Am J Epidemiol. 2004;159(3):277–83.PubMedCrossRef

45.

Lonn S, Ahlbom A, Hall P, Feychting M. Mobile phone use and the risk of acoustic neuroma. Epidemiology. 2004;15(6):653–9.PubMedCrossRef

46.

Muscat JE, Malkin MG, Shore RE, et al. Handheld cellular telephones and risk of acoustic neuroma. Neurology. 2002;58(8):1304–6.PubMed

47.

Schlehofer B, Schlaefer K, Blettner M, et al. Environmental risk factors for sporadic acoustic neuroma (Interphone Study Group, Germany). Eur J Cancer. 2007;43(11):1741–7.PubMedCrossRef

48.

Schoemaker MJ, Swerdlow AJ, Ahlbom A, et al. Mobile phone use and risk of acoustic neuroma: results of the Interphone case-control study in five North European countries. Br J Cancer. 2005;93(7):842–8.PubMedCrossRef

49.

Takebayashi T, Akiba S, Kikuchi Y, et al. Mobile phone use and acoustic neuroma risk in Japan. Occup Environ Med. 2006;63(12):802–7.PubMedCrossRef

50.

Warren HG, Prevatt AA, Daly KA, Antonelli PJ. Cellular telephone use and risk of intratemporal facial nerve tumor. Laryngoscope. 2003;113(4):663–7.PubMedCrossRef

Titel: Current State of Our Knowledge on Brain Tumor Epidemiology
verfasst von: Quinn T. Ostrom
Jill S. Barnholtz-Sloan
Publikationsdatum: 01.06.2011
Verlag: Current Science Inc.
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 3/2011
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-011-0189-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Neurosurgery for Brain Tumors: Update on Recent Technical Advances

Genomic Profiles of Glioma

Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence

Recent Advances in the Genetics of Hereditary Axonal Sensory-Motor Neuropathies Type 2

Molecular Mechanisms of PINK1-Related Neurodegeneration